Quarterly ResultApr 30, 2026, 05:56 PM
FBLG Q1 Net Loss $5M; DFU Trial Progress; $3M Direct Offering
AI Summary
FibroBiologics, Inc. reported a net loss of approximately $5.0 million for the first quarter ended March 31, 2026. The company made significant progress in its clinical pipeline, completing cGMP manufacturing and site onboarding for its Phase 1/2 clinical trial for diabetic foot ulcers (DFUs), with the first patient expected to be dosed in Q2 2026. Additionally, FibroBiologics raised $3M through a direct offering, regained Nasdaq compliance, and reported positive preclinical results for its burn and degenerative disc disease programs.
Key Highlights
- Raised $3M through a direct offering during Q1 2026.
- Regained compliance with all Nasdaq listing requirements.
- Reported a net loss of approximately $5.0 million for Q1 2026.
- Research and development expenses increased to $3.0 million in Q1 2026 from $1.8 million in Q1 2025.
- General and administrative expenses decreased to $2.1 million in Q1 2026 from $2.8 million in Q1 2025.
- Cash and cash equivalents were approximately $1.5 million at March 31, 2026.
- Subsequent to Q1, raised approximately $2.5 million net in a registered direct offering.
- Completed manufacturing and site onboarding for Phase 1/2 DFU clinical trial.